Two CCL3 haplotypes (HapA1 and Hap-A3) and two polymorphic positions shared by the haplotypes (Hap-2SNP (single nucleotide polymorphism)) were investigated together with CCL3L copy number (CN), for their role in HIV-1 disease. Hap-A1 was associated with protection from in utero HIV-1 infection: exposed uninfected (EU) infants had higher representation of wild type (WT)/Hap-A1 than infected infants (excluding intrapartum (IP)-infected infants), which maintained significance post maternal Nevirapine (mNVP) and viral load (MVL) correction (P ¼ 0.04; odds ratio (OR) ¼ 0.33). Mother-infant pair analyses showed the protective effect of Hap-A1 is dependent on its presence in the infant. Hap-A3 was associated with increased IP transmission: WT/Hap-A3 was increased in IP-transmitting vs non-transmitting (NT) mothers, and remained significant post mNVP and MVL correction (P ¼ 0.02; OR ¼ 3.50). This deleterious effect of Hap-A3 seemed dependent on its presence in the mother. Hap-2SNP was associated with lower CD4 count in the NT mothers (P ¼ 0.03). CCL3 Hap-A1 was associated with high CCL3L CN in total (P ¼ 0.001) and EU infants (P ¼ 0.006); the effect was not additive, however, having either Hap-A1 or high CCL3L CN was more significantly (P ¼ 0.0008) associated with protection from in utero infection than Hap-A1 (P ¼ 0.028) or high CCL3L CN (P ¼ 0.002) alone. Linkage disequilibrium between Hap-A1 and high CCL3L CN appears unlikely given that a Nigerian population showed an opposite relationship.
INTRODUCTION
Chemokines are a large superfamily of low-molecular-weight (B8-15 kDa), structurally related cytokines that mediate their biological functions through recruitment of cells bearing seventransmembrane G-protein-coupled receptors, as part of homoeostatic immune cell-trafficking or during inflammatory responses. Most chemokines can be divided into two major subgroups on the basis of the arrangement of the two N-terminal cysteine residues, depending on whether the first two residues are adjacent (CC) or have an amino acid between them (CXC; see review Colobran et al. 1 ). Three CC chemokines, namely CCL3 (formerly macrophage inflammatory protein-1a), CCL4 (formerly macrophage inflammatory protein-1b) and CCL5 (formerly RANTES), were shown to demonstrate HIV-1 suppressor activity early on, 2 which was later attributed to their binding to the CCR5 receptor, 3 the coreceptor R5 strains of HIV-1 use to gain entry into target cells. These chemokines have been shown in vitro to inhibit HIV-1 entry by competing with viral Env protein for binding 4, 5 as well as by downregulation of CCR5 surface expression; 6 however, whether these chemokines have a similar role in vivo is largely unknown. A number of genetic association studies suggest a role for these and other chemokines in HIV-1 infection (see review Colobran et al. 7 ). Of interest in this study is CCL3, which is encoded by two functional genes, namely CCL3 and CCL3La and in addition to these two genes, a third 'pseudogene' (CCL3Lb) has been described, 8, 9 which has been recently reported to have novel 5 0 exons giving rise to alternatively transcribed mRNA species.
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CCL3 is present as two copies per diploid genome, whereas CCL3La and CCL3Lb (collectively termed CCL3L) have been shown to exist in variable copies per diploid genome. 8, 9, 11, 12 These three genes have all been mapped to a narrow region on human chromosome 17.
The two isoforms of CCL3, namely CCL3 and CCL3La, differ by only three amino acids, yet CCL3La has been shown to be 30-fold more potent at inhibiting R5 HIV-1 infection compared with the CCL3 isoform. 13, 14 CCL3L copy number variation (CNV) and its role in HIV-1 infection have been the focus of a number of studies, however, not all studies agree to a role for CCL3L CNV. In a metaanalysis of nine published studies, recently conducted by Liu et al., 15 lower CCL3L CN was associated with higher risk of HIV-1 infection when one takes into account the specific population as different populations differ with respect to CCL3L CN means. Although in vitro studies show CCL3 to be less potent than CCL3La at R5 HIV-1 inhibition, there have been reports of single nucleotide polymorphisms (SNPs) and haplotypes within CCL3 impacting on both HIV-1 susceptibility as well as disease progression. [16] [17] [18] Interestingly, all these studies involve polymorphisms within various haplotypes that we believe are all part of larger haplotypes that we have described in South African Africans (SAAs) and Caucasians in an earlier study. 19 There are certain advantages to studying the role of haplotypes rather than a one-SNP-at-a-time approach in candidate genes studies, first, the proteins produced by an individual's genes occur in two polypeptide chains that correspond to maternal and paternal haplotypes and their folding as well as other properties are likely to be dependent on the arrangement of particular amino-acid combinations. 20 Variation in a population tends to be 'structured into haplotypes that are likely to be transmitted as a unit'. 20 Also, ethnically divergent population groups differ considerably regarding their haplotypic structures and select SNPs that can 'tag' more than one haplotype.
In a recent study conducted on serodiscordant Zambian couples, two CCL3 SNPs, namely rs5029410 (3 0 -untranslated region (UTR)) and rs34171309 (exon 3), were found to be significantly associated with lower viral load and increased risk of HIV-1 acquisition, respectively. 21 The role of CCL3 genetic variation in mother-to-child-transmission (MTCT) of HIV-1 has not been investigated, thus in this study we investigated the role of three CCL3 haplotypes (one encompassing the exon 3 rs34171309 SNP), previously identified in our SAA individuals, 19 for their role in MTCT HIV-1 transmission and in HIV-1 disease progression. In addition, the combined effect of CCL3 haplotypes and CCL3L CN was evaluated.
RESULTS

Cohort
A total of 314 HIV-1-infected SAA mothers and their infants (and 4 additional unmatched infants, that is, 318 infants), recruited as part of 4 mother-to-infant HIV-1 transmission cohorts in Johannesburg, South Africa, were used in this study. A detailed description of the four cohorts is given by Kuhn et al. 22 An additional 115 control, SAA HIV-1-uninfected mothers were also recruited. All available transmitting pairs (infant infected) and a random sample of approximately three non-transmitting (NT) pairs (mother infected but infant uninfected) per case were randomly selected from the cohorts. Of the 314 matching mother-infant pairs, 235 were mother-infant pairs where the infants were HIV-1 exposed but remained uninfected (EU) and their mothers are thus referred to as NT mothers. In addition there were three unmatched EU infants, thereby totalling 238 EU infants. There were 79 matched mother-infant pairs where the infant was determined HIV-1 infected and one additional unmatched infected infant thereby totalling 80 infected (INF) infants and 79 transmitting (TR) mothers. Of the 80 INF infants, 20 were infected in utero (IU; PCR positive at birth), 32 were infected intrapartum (IP; PCR negative at birth, positive at 6 weeks postpartum) and the remaining 28 were found to be infected at 6 weeks but had no birth sample available for determining the timing of transmission. The cohort individuals described by Kuhn et al. 22 were not all used in this study, thus Table 1 shows the distribution of this study's participants across the four cohorts. The median MVLs (copies per ml) and CD4 counts (cells per ml) for the broad groups are also shown in Table 1 .
Antiretroviral drugs
As this study aimed to investigate the role of select genetic variations on mother-to-infant HIV-1 transmission, the role had by the various antiretroviral drugs administered in the four cohorts needs to be addressed. Study participants were classified according to whether the mothers were administered no NVP (noNVP) or a single-dose maternal NVP (mNVP) during labour. All infants received a single dose of NVP. Table 1 also shows the distribution of mothers and infants after stratification according to mNVP (with MVLs and CD4 counts). Single-dose NVP administration to the mother during labour serves to only reduce IP HIV-1 infant infection as mNVP does not exert its protective effect by reducing the MVL (insufficient time; mNVP vs noNVP MVL: P ¼ 0.6; Mann-Whitney U-test), but by the increased NVP in the infant acquired through placental transfer. Thus, mNVP administration (and subsequent infant NVP administration) has no effect on IU infection, which has occurred before NVP exposure. To correct for the effect of antiretroviral drugs, in addition to analysing the data without taking drugs into account, logistic regression was used to correct for the effect of mNVP, and mothers and infants that were administered other antiretroviral drugs were excluded from this part of the analysis. Figure 1 shows the SNPs as well as the nucleotide (minor allele) composition of these two haplotyes relative to a schematic representation of the CCL3 gene. These two haplotypes overlap at two SNP positions as indicated on Figure 1 . Thus, in addition to investigating the role of each haplotype individually in both HIV-1 mother-to-child transmission and HIV-1 disease (in the mothers), we were also able to independently investigate the effect of the minor alleles of the A/G p þ 1245 (rs1719130) and C/G p þ 1728 (rs1063340) SNPs (termed Hap-2SNP). This is not only a count of individuals heterozygous for Hap-A1 and Hap-A3 (that is, an individual having both haplotypes) as homozygosity for either Hap-A1 or Hap-A3 would result in homozygosity for Hap-2SNP.
Linkage disequilibrium and Hardy-Weinberg Mother (both infected and controls) and infant groups were grouped separately and analysed for both pairwise linkage disequilibrium (LD) between all minor alleles in the two haplotypes (Hap-A1 and Hap-A3) and well as for deviation from HardyWeinberg for the two tag SNPs and the Hap-2SNP genotypic data. All minor alleles in both haplotypes were in perfect LD with D' ¼ 1 for all pairwise combinations and all were significant with P'so0.01. In addition, no significant deviations from Hardy-Weinberg equilibrium were noted for the three haplotypes.
Frequency of CCL3 haplotypes in the SAA population The minor allele frequencies of the three haplotypes as well as the genotypic frequencies are listed in Table 2 . The haplotype frequencies of the control mothers, infected mothers as well as the total infant group did not show any noticable over or underrepresentation in any one group over the other, and comparisons between the control and infected mothers did not reveal any trends or significant differences (data not shown).
Given that Hap-2SNP involves SNPs shared by Hap-A1 and Hap-A3, it is not surprising that it is the most prevalent of the haplotypes in the SAA population group with an allelic frequency of B18.9% (averaged across the three groups) and heterozygosity for Hap-2SNP was found in B31% of the SAA population group. Hap-A1 is also a prevalent haplotype in this population group with an average allelic frequency of B13.5% whereas Hap-A3 was the least prevalent of the haplotypes with an allelic frequency of 5%. Homozygosity for Hap-A3 was rarely detected.
CCL3 haplotypes and maternal HIV-1 disease progression VL and CD4 count comparisons between HIV-1-infected mothers (total and NT mothers) harbouring Hap-A1, Hap-A3 or Hap-2SNP to mothers lacking the haplotypes are shown in Table 3 . The cohorts used in this study were designed to study HIV-1 MTCT, and thus a 3:1 ratio of NT:TR mothers is skewed in terms of TR mother overrepresentation compared with a cross-sectional study where the rate of MTCT would be at least twofold less. Thus, to determine the role of CCL3 haplotypes on markers of disease progression, mothers were also analysed in the absence of TR mothers (that is, NT mothers). Strong trends in the total mother group were seen with Hap-2SNP heterozygosity as well as Hap-2SNP heterozygosity combined with Hap-2SNP homozygosity (that is, at least one copy of Hap-2SNP) and lower CD4 count (P ¼ 0.059 and 0.056, respectively), which both proved to be significant upon analysis of the NT mothers alone (P ¼ 0.034 and 0.032, respectively). Hap-A1 also showed a trend of association with low CD4 count in the NT mothers (P ¼ 0.067). 
Role of CCL3 haplotypes and CCL3L copy number in HIV-1 infection M Paximadis et al
A role for Hap-A1 in infant protection from HIV-1 infection Hap-A1 comparisons between all groups of TR and NT mothers revealed no significant associations of this haplotype with any particular group (data not shown). Table 4 shows comparisons between EU infants and infected infant groups/subgroups with respect to Hap-A1 heterozygosity (WT/Hap-A1). EU infants had higher representation of Hap-A1 heterozygosity compared with INF infants (P ¼ 0.06; odds ratio (OR) ¼ 0.53), and a trend was maintained post MVL correction (P ¼ 0.07; OR ¼ 0.53) and mNVP correction (P ¼ 0.05; OR ¼ 0.50), but was lost upon combined correction for MVL and mNVP, without much change to the OR (P ¼ 0.10; OR ¼ 0.55). Comparison of EU infants to IP and IU infants revealed that it is the IU infants that are underrepresented with respect to WT/Hap-A1 and although not significant when compared with EUs (P's ¼ 0.09-0.15 across comparisons), the ORs were low and ranged from 0.29 to 0.32 ( Table 4 ). Given that the IU group is fairly small (n ¼ 20), and given that the infected infant group of unknown (that is, IP or IU) infection route (n ¼ 28) are likely to have a higher proportion of IU infections than IP infections (see rationale in 'Materials and methods' section under 'Comparisons and Analyses'), we compared EU infants to infected infants (termed INF-2) after exclusion of known IP-infected infants. Table 4 shows that EU infants had significantly higher representation of WT/Hap-A1 compared with INF-2 infants (P ¼ 0.02; OR ¼ 0.16), and furthermore this significance was maintained post MVL (P ¼ 0.03; OR ¼ 0.34), mNVP (P ¼ 0.02; OR ¼ 0.30) and combined MVL and mNVP correction (P ¼ 0.04; OR ¼ 0.33). This result strongly suggests that Hap-A1 is having a role in protection from HIV-1 in utero infection.
To further investigate the role of Hap-A1, we looked at motherinfant pairs with respect to concordance and discordance in possession of the WT/Hap-A1 genotype. Figure 2a shows that the protective effect of WT/Hap-A1 occurs at the level of the infant. Although concordance for the genotype (M þ I þ ) still reveals NT/EU mother-infant pairs having higher representation than both IU-TR/IU and the TR-2/INF-2 mother-infant pairs, this is not statistically significant. In the discordant combination where the genotype is absent in the mother and present in the infant (M À I þ ), TR-2/INF-2 mother-infant pairs have significantly less WT/Hap-A1 than NT/EU mother-infant pairs (P ¼ 0.023) and although IU-TR/IU mother-infant pairs had zero representation of WT/Hap-A1, this association did not reach significance. 
A role for Hap-A3 in maternal HIV-1 transmission Comparison of infected infant groups to EU infants with respect to Hap-A3 and Hap-2SNP failed to show a role for these two haplotypes with respect to HIV-1 infant protection (data not shown). Table 5 shows comparisons between NT mothers and TR mother groups/subgroups with respect to Hap-A3 heterozygosity (WT/Hap-A3) and Hap-2SNP homozygosity.
NT mothers had significantly lower representation of WT/ Hap-A3 compared with IP-TR mothers (P ¼ 0.04; OR ¼ 2.94), which maintained significance post-MVL correction (P ¼ 0.02; OR ¼ 3.42), post-mNVP correction (P ¼ 0.03; OR ¼ 3.17) and post combined correction for MVL and mNVP (P ¼ 0.02; OR ¼ 3.50).
Minor allele homozygosity at Hap-2SNP showed a trend of underrepresentation in NT mothers compared with TR mothers and IP-TR mothers in the total group comparisons (P ¼ 0.08; OR ¼ 3.95 and P ¼ 0.06; OR ¼ 5.92, respectively), which were maintained post-MVL correction (P ¼ 0.06; OR ¼ 4.51 and P ¼ 0.08; OR ¼ 5.60, respectively). A trend was maintained only in the NT vs IP-TR comparison post-mNVP and post the combined mNVP and MVL correction (P ¼ 0.06; OR ¼ 6.06 and P ¼ 0.07; OR ¼ 6.05, respectively). As IU-TR mothers had no representation of Hap-2SNP homozygosity, we compared NT mothers to TR mothers after removal of the IP-TR mother subgroup (that is, TR-2 equivalent to the INF-2 infant group and predominantly IU-TR mothers). No significant associations were seen with respect to NT vs TR-2 and Hap-2SNP homozygosity (Table 5) .
These results point to a role for Hap-A3 in increasing the likelihood of IP mother-to-child HIV-1 transmission. Hap-2SNP also shows a trend towards increased IP transmission, however, as the frequency of Hap-2SNP homozygosity is very low (2.34% in total HIV-1-infected mothers, Table 2 ), the confidence intervals in these comparisons are very large hence larger sample numbers would be needed to verify this result.
Concordant and discordant mother-infant comparisons with respect to WT/Hap-A3 did not reveal any significant associations, however, Figure 2b clearly shows that the relationship of high WT/ Hap-A3 being associated with a greater likelihood of IP transmission seemed dependent on the genotype being present in the mother as in both M þ I þ and M þ I À mother-infant groups, IP-TR/IP mother-infant pairs have at least double the representation of WT/Hap-A3 compared with the NT/EU mother-infant pairs. Conversely, in the M-I þ mother-infant group, IP-TR/IP motherinfant pairs have no representation of WT/Hap-A3 compared with 5.2% in the NT/EU mother-infant pairs (Figure 2b ). CCL3 haplotypes and CCL3L gene CN Results of Mann-Whitney U-test comparisons in the infant groups with regard to CCL3L CN alone as well as CCL3L CN and CCL3 haplotypes are listed in Table 6 .
As we have previously seen within this cohort, 22 EU infants have statistically higher CCL3L CN compared with INF infants (P ¼ 0.004). When we compared the possession of at least one copy of Hap-A1 (that is, homozygotes and heterozygotes) and their CCL3L CN, we found that within the total infant group, infants with high CCL3L CN were very significantly associated with possession of Hap-A1 (P ¼ 0.001). This was due to the EU infants as EU infants with high CCL3L CN also tend to possess at least one copy of CCL3 Hap-A1 (P ¼ 0.006) compared with INF infants (P ¼ 0.141). On the other hand, possession of high CCL3L CN and at least one copy of Hap-A3 failed to show any significance, however, when Hap-2SNP was analysed in the same manner, within the total infant group, high CCL3L CN and possession of at least one copy of Hap-2SNP was also significant (Po0.001) and seen within both the EU (P ¼ 0.011) and INF infants (P ¼ 0.029). No significant associations or trends between CCL3L CN and the To determine whether another African population showed a similar strong association with CCL3L CN and Hap-A1, we made use of SNP data available for the Yoruban (YRI) population group (Nigeria) from the HapMap project (http://www.hapmap.org) and CCL3L CN data available for the same group using supplementary data from Campbell et al. 23 Although SNP data for only two SNP positions (rs1130371 and rs1719134) found in Hap-A1 were available in HapMap, we made the assumption that Hap-A1 is present within this population group and used the rs1130371 SNP data as a putative 'tag' for Hap-A1 to test for the association of CCL3L CN and the presence or absence of the minor allele of the rs1130371 SNP (Mann-Whitney U-test). Results show that Hap-A1 was significantly associated with CCL3L CN, however, surprisingly, and in contrast to our study population, Hap-A1 in the YRI population is associated with low CCL3L CN (P ¼ 0.005). What we did notice is that the two populations differed with respect to CCL3L CN distribution with the YRI population having a median CCL3L CN of 4 (range 2-8) whereas our study population has a median of 5 (range 1-10), which is similar to the distribution seen in healthy-uninfected SAA adults (median ¼ 5, range ¼ 0-9, N ¼ 240; unpublished data).
As high CCL3L CN is significantly associated with infant protection from HIV-1 infection, and as Hap-A1 is significantly associated with protection from IU HIV-1 infection (overrepresentation in EU infants vs INF-2 infant group), the significant association of CCL3 Hap-A1 and high CCL3L CN warrants further investigation. To determine whether there is an additive effect of CCL3 Hap-A1 and high CCL3L CN, we compared EU infants and INF-2 with both these genetic features to those with neither. Table 7 shows that having both these genotypes (P ¼ 0.033) is not more statistically significant than each genotype alone, that is, suggesting no additive effect. However, when we compared the same groups with respect to having either one of these protective genotypes, that is, at least one copy of CCL3 Hap-A1 or high CCL3L CN, we found that this combination is more significant (P ¼ 0.0008) than the effect of each genotype alone (Table 7) . Furthermore, when we performed a logistic regression analysis using stratified CCL3L CN and CCL3 WT/Hap-A1 on the EU vs INF-2 data set, the effect of CCL3L CN remained significant (P ¼ 0.01; OR ¼ 0.38) and although CCL3 Hap-A1 lost significance upon adjustment for the effect of CCL3L CN, it maintained a strong trend (P ¼ 0.055; OR ¼ 0.42). These results suggest that both these genetic factors are protective in the context of infant IU infection, however, CCL3L CN is the stronger of the two and likely to be responsible for why an additive effect is not evident. DISCUSSION CCL3, through its CCR5-mediated signalling, has been shown in vitro to be inhibitory to HIV-1 entry. An in vivo role for CCL3 in HIV-1 disease has largely been shown through animal model The presence ( þ ) or absence ( À ) of at least one copy of the haplotype (that is, heterozygotes and homozygotes scored equally).
Role of CCL3 haplotypes and CCL3L copy number in HIV-1 infection M Paximadis et al studies involving both mice and non-human primates. [24] [25] [26] [27] A role for CCL3 in HIV-1 infection in humans has been suggested primarily through genetic association studies, where low CCL3L gene CN has been shown in numerous studies to be associated with increased adult and infant/child HIV-1 susceptibility. 10, 11, 22, [28] [29] [30] A role for CCL3 in cell-mediated immune responses to HIV-1 has also been suggested in studies by Shalekoff et al. 31 and Dolan et al.
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As CCL3 is encoded by two functional genes (CCL3 and CCL3L), the contribution of CCL3, in combination with CCL3L CN, on HIV-1 disease in a SAA population group was investigated. Although the CCL3 isoform is far less potent than the CCL3La isoform at R5 HIV-1 inhibition in in vitro studies, this is not the only effect/ function that may be of significance in an in vivo scenario. Furthermore, the individual contribution of these two genes to overall CCL3 production is still largely unknown mainly due to the absence of a monoclonal antibody that can differentiate the two protein isoforms. A recent study that has tried to address this question by comparing mRNA transcripts of the two genes, as well as looking at CCL3 production in a Caucasian cohort, found that CCL3 expression predominates in both mRNA and protein, and consequently one of their main conclusions is that, in terms of biological significance, the variation in CCL3 may be potentially more relevant than CCL3L CNV. 33 However, if CCL3La is far more potent than CCL3, then much less protein may be required in vivo, and small changes in the abundance of CCL3La may thus have larger consequence and hence may need to be regulated more finely. Nonetheless, the contribution of the CCL3 isoform to HIV-1 disease is largely understudied.
In a previous study in which we sequenced the CCL3 genes of 43 African mother-infant pairs, two haplotypes comprised of the minor alleles of seven SNPs (designated Hap-A1 and Hap-A3) were identified at relatively high frequencies (45%) within this population group. The two haplotypes overlapped in two out of the seven positions and it is highly probable that these two polymorphic positions represent an ancestral haplotype (termed Hap-2SNP in this study), which accumulated additional polymorphisms in two separate pathways resulting in Hap-A1 and Hap-A3. These two polymorphic positions are also found on a prevalent five SNP haplotype described in a South African Caucasian population, 19 further supporting Hap-2SNP representing an ancestral core haplotype. Genotypic assays designed to detect Hap-A1 and Hap-A3 in this study thus also allowed the opportunity to study the effect of these two polymorphic positions independently. In addition, the availability of CCL3L CN data for the same cohort 22 allowed us to investigate the combined effect of the two genes than encode the CCL3 chemokine.
Hap-A1, found in high frequency within the SAA population group (13% allelic frequency), is comprised of the minor alleles of a core promoter SNP, three intronic SNPs, two exonic SNPs (exons 2 and 3) and one 3 0 -UTR SNP. This haplotype is of particular interest as it harbours SNPs that have been reported in previous genetic association studies to impact on HIV-1 susceptibility as well as disease progression. [16] [17] [18] 21 An investigation of its role in HIV-1 disease, using VL and CD4 count as markers of disease progression in the mothers, revealed a strong trend of association with lower CD4 count in the NT mothers. Hap-A1, however, had no role in maternal transmission of HIV-1 as evidenced by similar representation of this haplotype among TR and NT mothers (o5% difference). Hap-A1 heterozygosity on the other hand was more highly represented among EU infants when compared with INF infants. Comparison of EU infants to infected infants in the absence of the IP-infected infant group revealed a significantly higher representation of Hap-A1 in the EU infants, which was maintained through all corrections performed and, in addition, was significantly higher in NT/EU mother-infant pairs compared with predominantly IU-infected infant-mother pairs (that is, after exclusion of the IP-TR/IP pairs). These results strongly suggest a protective role for Hap-A1 in acquisition of HIV-1 infection by the infant through the in utero mode of transmission.
A role for Hap-A1 in HIV-1 protection is consistent with select studies that have looked at one or more SNPs that are part of this haplotype. Gonzalez et al. 16 were the first to find an association with two SNPs (C/T p þ 199 and C/T p þ 545; Figure 1 ) in African Americans (AAs) with homozygosity for the minor allele at both positions (TT) being associated significantly with lower risk of HIV-1 acquisition, however, no effect was seen on disease progression within the same group. Two other studies, 17, 18 both investigating SNPs associated with HIV-1 risk of infection in the same intravenous-drug-using cohort (ALIVE), found opposite associations for different SNPs that are present in Hap-A1. Shrestha et al. 18 report an increased susceptibility among AA intravenous-drug-users with homozygosity for the minor allele of C/T p þ 954 (which they state to be in LD with C/T p þ 545 and A/G p þ 1245), whereas Modi et al., 17 report three SNPs, two correlating to C/T p þ 199 and G/T p þ 1428 (which they report to be in LD with C/T p þ 545, C/T p þ 954 and A/G p þ 1245) to be significantly elevated among highly exposed, persistently HIV-1-uninfected AAs compared with HIV-1-infected AA seroconverters. Thus, both studies report opposite associations for SNPs, which appear to be in LD with each other and representative of the Hap-A1 haplotype described in our African cohort. In a recent study, which looked at Zambian HIV-1 serodiscordant couples, out of 63 SNPs studied in CCL2, CCL3, CCL4 and CCL5, only 2 SNPs, both in CCL3, were highlighted as having a role; a 3 0 -UTR SNP was associated with lower VL in seroconverters and again a Hap-A1 SNP, G/T p þ 1428 (rs34171309), was found to be associated with increased risk of HIV-1 acquisition in the serodiscordant couples. 21 This is the only study to our knowledge that has reported an association for a Hap-A1-associated CCL3 SNP in another sub-Saharan African population group, again highlighting a role for Hap-A1 in HIV-1 susceptibility, albeit an opposite effect from what we saw in our MTCT cohort. Heterosexual, intravenous and in utero mother-infant HIV-1 infection are three very different modes of transmission, and it is very likely that the role of this chemokine may differ depending on the mode of transmission.
Hap-A3 and Hap-2SNP did not show any association with regard to infant HIV-1 protection. They were, however, more highly represented in mothers that transmitted HIV-1 to their infants through the IP route compared with the NT mothers. Hap-A3 heterozygosity was significantly higher in IP-TR mothers compared with NT mothers and this remained significant after all corrections for MVL and mNVP. Furthermore, from the concordance/ discordance comparisons involving this haplotype, it appears that Hap-A3 has a role in increased IP MTCT only when present in the mother. Hap-A3 is comprised of the minor alleles of four intronic SNPs and three 3 0 -UTR SNPs. The 3 0 -UTR regions of metazoan genes are microRNA target-rich regions raising the question as to The presence of at least one copy of CCL3 Hap-A1 (that is, homozygotes and heterozygotes).
b High CCL3L CN X5.
c Individuals with CCL3 Hap A1 (at least one copy) and a high CCL3L CN.
d Individuals with either CCL3 Hap A1 (at least one copy) or a high CCL3L CN.
Role of CCL3 haplotypes and CCL3L copy number in HIV-1 infection M Paximadis et al whether the three 3 0 -UTR Hap-A3 SNPs form part of any microRNA target sequences that function to modulate CCL3 RNA transcription. Although Hap-2SNP homozygosity was also higher in IP-TR mothers compared with NT mothers, the small sample numbers in this comparison make this result tentative as indicated by the large confidence intervals.
Hap-2SNP homozygosity as well as at least one copy of Hap-2SNP showed strong trends of association with lower CD4 counts in the total HIV-1-infected mothers and this proved to be significant also when NT mothers were analysed separately. The strong trend of Hap-A1 also associating with lower CD4 count in the NT mothers is probably attributable to the two SNPs in Hap-2SNP that are part of Hap-A1. The two polymorphisms that constitute Hap-2SNP are not located in the exons but in intron 2 (p þ 1245 A/G) and in the 3 0 -UTR region (p þ 1728 C/G) and thus whether either of these two allelic variations (or both) impact on CCL3 gene expression will be worthy of future investigation. These results do, however, suggest a role for CCL3 in HIV-1 disease progression.
Thus, all three CCL3 haplotypes investigated in this study appear to have some effect within the context of HIV-1 MTCT and disease progression in a sub-Saharan African population group, however, it is important to state that first the numbers in this cohort are not large and the absence of correction for multiple tests makes it imperative that these associations are tested in larger cohorts with more conservative statistical analyses. Studies such as these, however, are important to lay the groundwork regarding potential genetic features that can be looked at in larger population groups and that can be targeted in terms of determining what genetic variation impacts on CCL3 expression and function.
An unexpected finding in this study was the highly significant association that was seen with the combination of CCL3L CN and two of the CCL3 haplotypes, namely Hap-A1 and Hap-2SNP. The presence of at least one copy of Hap-A1 and Hap-2SNP was very significantly associated with high CCL3L CN in the total and well as in the EU infant groups and also within the INF infants with regard to the Hap-2SNP alone. Even though Hap-2SNP forms part of Hap-A1 and Hap-A3, CCL3L CN and CCL3 Hap-A3 were not found to be significantly associated, suggesting that it is Hap-A1, the more prevalent of the two seven SNP haplotypes is the major contributor in the Hap-2SNP association seen. Similar comparisons (Mann-Whitney U-test) carried out in the mothers failed to show similar associations.
What does this significant association of CCL3 Hap-A1 and CCL3L CN imply? A number of possibilities come to mind, first, as Hap-A1 was higher in the EU infants compared with the INF infants (particularly in the IU-enriched-infected group: INF-2), and EU infants have significantly higher CCL3L CN compared with INF infants, then a combination of the two might be expected to show an additive contribution of the two 'protective' traits. Comparison of EU vs INF-2 infants with respect to having Hap-A1 and a high CCL3L CN failed to show an additive effect as the association was not more significant than either genotypic feature alone. However, having Hap-A1 or high CCL3L CN was very significantly (P ¼ 0.0008) associated with higher representation in the EUs compared with the INF-2 infants, and more significant than the individual associations. Logistic regression analysis of CCL3 Hap-A1 and CCL3L CN in the infant groups also showed that CCL3L CN remains significant when accounting for CCL3 Hap-A1, and CCL3 Hap-A1 maintained a strong trend when accounting for CCL3L CN. These results suggest that these two genetic factors are both exerting a protective effect, with high CCL3L CN being the stronger of the two, and have probably undergone separate evolutionary selection.
Another possibility is that there may be some LD between CCL3 Hap-A1 with high CCL3L CN, however, if so, one would expect to see a similar relationship in the corresponding mothers that was not the case. The infant group, however, is predominantly composed of EU infants, and the mothers, are all HIV-1 infected and so are likely to have differing CCL3 Hap-A1 and CCL3L CN distributions. A number of studies have investigated LD between SNPs and regions of CNV in an attempt to try and find reliable 'tag' SNPs for CN polymorphisms 23, [34] [35] [36] [37] and the general consensus seems to be that there is a high degree of LD between simple biallelic CN polymorphisms and the surrounding SNPs, however, multiallelic CN polymorphisms (like CCL3L) tend to show less LD with surrounding SNPs. 23 To see whether this result was true for another, non-infected African population group, we used data available for the Yoruban (Nigeria) population from HapMap. Unexpectedly, this data also showed a significant association between a Hap-A1-associated SNP and CCL3L CN, although it was the reverse association to the one seen in our study. Although, we cannot be certain that Hap-A1 is in fact present in this population group, it seems likely that it is as it appears to be present in AA population groups. 17, 18 Thus, given these two contrasting results for two African population groups makes it unlikely that there is LD between CCL3 Hap-A1 and CCL3L CN, and the strong association more than likely reflects enrichment of two mutually exclusive protective traits in a group of infants that were exposed to HIV-1 and remained uninfected.
In conclusion, this study has examined the role of three African CCL3 haplotypes in HIV-1 infant susceptibility, maternal HIV-1 transmissibility and HIV-1 disease progression in the mothers and suggests a role for this gene, together with CCL3L in HIV-1 disease. We believe this study has highlighted in particular the complexity that exists in this genome region, and the difficulty in trying to understand the contribution to HIV-1 disease of individual, closely related genes, that encode for a protein that to date cannot be easily differentiated.
MATERIALS AND METHODS
Cohort HIV-1 infection status
The infant's infection status was determined by a HIV-1 DNA PCR test (Amplicor version 1.5, Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). The VL determinations were done on maternal delivery samples using the Roche Amplicor RNA Monitor assay version 1.5 (Roche Diagnostic Systems) and the CD4 T-cell counts were determined using the commercially available FACSCount System from Becton Dickinson (San Jose, CA, USA).
In the case of TR mothers, 23% in our study reported any breastfeeding vs 16% of NT mothers (not significant). The average duration of breastfeeding for those who initiated any breastfeeding was 14 days. By extrapolation the effect of breastfeeding would be negligible in this cohort. Moreover, as breastfeeding and IP transmission are thought to occur across mucosal surfaces, which are different to IU transmission, combining the majority IP with a tiny proportion of breastfeeding would not confound the genetic outcomes with transmission likelihood.
This study was approved by the University of the Witwatersrand Committee for Research on Human Subjects and the Institutional Review Board of Columbia University, and signed informed consent was obtained from all mothers who participated in the study.
LD between haplotype SNPs
Although the minor alleles involved in these two haplotypes (Hap-A1 and Hap-A3) were previously confirmed to be syntenic by cloning out of respective haplotypes and in addition the SNPs were always found associated with each other in all individuals that were genotyped, 19 to further confirm that all the alleles were in complete linkage, pairwise LD between every two minor allele combination in the haplotype (that is, 21 pairwise combinations for a seven SNP haplotype) was estimated using the method described by Lewontin. 38 The LD coefficient D was calculated (D ij ¼ HF ij -p i p j ) and subsequently normalized (D') or standardized by the maximum value it can take (D max ) using the formula D' ij ¼ D ij /D max . HF ij is the frequency of the haplotype carrying alleles i and j, p i and p j are the frequencies of alleles i and j, respectively, and D max is either min (p i p j, (1- 40 . D' values are defined in the range ( À 1 to 1) with a value of '1' representing perfect Role of CCL3 haplotypes and CCL3L copy number in HIV-1 infection M Paximadis et al disequilibrium. The statistical significance of the LD between each of the allele pairs was evaluated by the approximate w 2 described by Liau et al.
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Development of a real-time PCR assay for haplotype genotyping
As both haplotypes were comprised of alleles in complete LD, a SNP unique to each haplotype (that is, not shared between haplotypes) was selected for development of a real-time PCR assay for the detection of the haplotype, thereby using the SNP position as a 'tag' or representation of the haplotype (see Figure 1 for tag SNPs). We developed SYBR Green realtime PCR assays to detect the SNPs using allele-specific PCR with two allele-specific primers designed with their 3 0 -end bases complementary to one of two SNP variants present (termed WT and mutant (that is, Hap-A1 or Hap-A3)) and one common primer (that is, reverse or forward depending on orientation of allele-specific primers). Two PCR reactions were thus conducted for each sample, one with each of the WT and mutant primers. For the detection of Hap-A1, both allele-specific primers (forward primers) were designed with a lock nucleic acid modified 3 0 -end base (5 0 -TAGCATGACAGCATCACTAY-3 0 ) and a standard reverse primer (5 0 -TGGAGACCTGCATGATTCT-3 0 ). For Hap-A3, the best results were obtained by using a combination of a lock nucleic acid modified WT (that is, 'C' base) detection reverse primer, a standard mutant (that is, 'T' base) detection reverse primer (5 0 -GAGCAGTTGAGGAAGGCAR-3 0 ) and a common forward primer (5 0 -GAAGAGTCAAGGAGAAAGAAGG-3 0 ). Each 10 ml reaction contained 1 Â Applied Biosystems SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 10 pmol of each forward and reverse primer and B30-80 ng DNA template. The PCR reactions were run in an Applied Biosystems 7500 Real-Time PCR system. Initial 10 min denaturation at 95 1C was followed by 40 cycles of 15 s denaturation at 95 1C, annealing at 60 1C for 20 s and extension at 72 1C for 1 min. To analyse the PCR data, the cycle threshold, (C T, the minimal fluorescence above which a sample is determined positive) was determined and used to calculate DC T values (difference in C T ) by subtracting the C T of the WT reaction from the mutant reaction. Heterozygous individuals had DC T between 0 and 1.5, whereas homozygous WT and mutant individuals had DC T values X7 and X À 7, respectively. Plasmid DNA harbouring cloned CCL3 genes with the two respective haplotypes as well as genomic DNA from individuals of known genotype 19 were used to optimize the assays.
Hardy-Weinberg equilibrium
All genotypic data were tested for deviation from Hardy-Weinberg equilibrium using the conventional Monte Carlo exact test of Guo and Thompson 40 implemented through the freely available online computer program Tools For Population Genetic Analyses (TFPGA: version 1.3; http:// www.marksgeneticsoftware.net/_vti_bin/shtml.exe/tfpga.htm).
Comparisons and analyses
In addition to comparing NT mothers and EU infants to TR and INF infant groups and subgroups (IP and IU), respectively, a number or other comparisons were made, which are as follows:
(i) Stratification of mother and infants according to single dose mNVP, and no maternal NVP (noNVP) revealed that the mNVP subgroup had unexpectedly significantly more infected infants in total compared with the noNVP subgroup (31.5% vs 18.3%; P ¼ 0.013), but as expected, significantly proportionally less IP infants in the mNVP subgroup compared with the noNVP subgroup (11/46, 24% vs 18/25, 72%; Po0.001) as mNVP is known to affect IP transmission/infection. Out of the 23 infants of unknown mode of infection within these NVP-stratified groups, 22/23 infants fell within the mNVP group compared with 1/23 that fell within the noNVP group (Po0.001), suggesting that the higher number of infections in the mNVP group is due to these infants of unknown infection route, and further suggesting that a large proportion of these infants are likely to have been IU. Thus, in trying to determine whether one of the CCL3 haplotypes was showing an association with in utero HIV-1 infection, we also analysed the data by comparing EU infants to infected infants after removal of the IP-infected infants from the group. This subgroup was designated as INF-2.
(ii) CCL3 genotypes found to be associated with either infant susceptibility of maternal transmissibility were further analysed by looking at the level of concordance or discordance between mother-infant pairs with respective genotypes.
Fisher's exact tests were used to calculate statistical significances and exact 95% confidence intervals of ORs of genotype frequency differences (Simple Interactive Statistical Analysis 41 ). Two-sided tests were used and
